Watch AXSM. Know when insiders buy.
One email the day a filing lands. Free.
Work order
46
WATCH · insiders 25, shorts 66
Insiders, 90 days
−$2.1M
net selling · 0 buys, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
3 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $10.8BP/E —DIV YIELD —FCF YIELD -0.66%REV TTM $776.6M +56.9%NET INCOME −$191.6MNET CASH $131.9M52W 114.10 – 255.17SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $218.4M | +45.5% | — | −$49.6M | −$51.3M | — | -0.99 | −$33M | $450K | −$33.4M | Aug 10 |
| Q1 2026 · Mar 31 | $191.2M | +57.4% | — | −$63.4M | −$64.5M | — | -1.26 | −$20.7M | $121K | −$20.8M | Aug 10 |
| Q4 2025 · Dec 31derived | $196M | +65.0% | — | −$27M | −$28.6M | — | -0.55 | −$18.7M | $71K | −$18.7M | Feb 23 |
| Q3 2025 · Sep 30 | $171M | +63.2% | — | −$46.1M | −$47.2M | — | -0.94 | $1M | $58K | $988K | Nov 3 |
| Q2 2025 · Jun 30 | $150M | +72.1% | — | −$36.7M | −$48M | — | -0.97 | −$32.4M | $13K | −$32.4M | Aug 10 |
| Q1 2025 · Mar 31 | $121.5M | +62.0% | — | −$57M | −$59.4M | — | -1.22 | −$43.4M | $338K | −$43.7M | Aug 10 |
| Q4 2024 · Dec 31derived | $118.8M | +66.0% | — | −$72.6M | −$74.9M | — | -1.54 | −$26.2M | $30K | −$26.2M | Feb 23 |
| Q3 2024 · Sep 30 | $104.8M | +81.3% | — | −$62.6M | −$64.6M | — | -1.34 | −$18.6M | $90K | −$18.7M | Nov 3 |
| Q2 2024 · Jun 30 | $87.2M | — | — | −$78M | −$79.3M | — | -1.67 | −$30.1M | $52K | −$30.2M | Nov 3 |
| Q1 2024 · Mar 31 | $75M | — | — | −$67.3M | −$68.4M | — | -1.44 | −$53.5M | $98K | −$53.6M | Nov 3 |
| Q4 2023 · Dec 31derived | $71.5M | — | — | −$98.3M | −$98.7M | — | -2.13 | −$30.4M | $7K | −$30.4M | Feb 23 |
| Q3 2023 · Sep 30 | $57.8M | — | — | −$62.1M | −$62.2M | — | -1.32 | −$53.5M | $371K | −$53.9M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $638.5M | — | −$166.8M | −$183.2M | -28.7% | -3.68 | −$93.4M | $480K | −$93.9M | — | — |
| FY2024 · to Dec 31 | $385.7M | — | −$280.6M | −$287.2M | -74.5% | -5.99 | −$128.4M | $270K | −$128.7M | — | — |
| FY2023 · to Dec 31 | $270.6M | — | −$231.8M | −$239.2M | -88.4% | -5.27 | −$145.1M | $582K | −$145.7M | — | — |
| FY2022 · to Dec 31 | $0 | — | −$179.8M | −$187.1M | — | -4.60 | −$116.5M | $702K | −$117.2M | — | — |
| FY2021 · to Dec 31 | — | — | −$124.7M | −$130.4M | — | -3.47 | −$108.2M | $308K | −$108.5M | — | — |
| FY2020 · to Dec 31 | — | — | −$99.1M | −$102.9M | — | -2.77 | −$78.5M | $46K | −$78.5M | — | — |
Every number comes from Axsome Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.